Competing interests
GSK/Novartis, T.v.d, P.K., Cancer
ONCOLOGY, CANCER
None of the authors have conflicts of interest directly related to the present work. V.D., P.K., J-L.C., L.M., R.P., Z.D., X.C., R.S., F.R., L.C., D.V., D.L., M. Paesmaens: no competing interests. L.B.: financial interests, institutional, funding: AstraZeneca; financial interests, personal, funding: Fondation contre le Cancer. D.L.: financial interests, personal, advisory board, honoraria: AstraZeneca, Eli Lilly, Immunomedics, MSD, Pfizer, Roche, 4D Pharma, Daiichi Sankyo, Novartis, Gilead; financial interests, personal, royalties, travel support: Pfizer, Roche, MSD, AstraZeneca. P.A.: financial interests, personal, advisory board, consulting: Boehringer Ingelheim, Macrogenics, Roche, Novartis, Amcure, Servier, G1 Therapeutics, Radius, Deloitte; financial interests, personal, advisory board, honoraria: Synthon, Amgen, Novartis, Gilead; financial interests, personal, royalties, travel support: Amgen, MSD, Pfizer, Roche; financial interests, institutional, research grant: Roche. C.M.: financial interests, personal, royalties, travel support: Mundipharma, Amgen, Servier Deutschland GmbH, AbbVie; financial interests, personal, advisory board, honoraria: AbbVie; financial interests, personal, advisory board: Celgene/BMS. K.P.: financial interests, institutional, advisory board: AstraZeneca, Novartis, Roche, Vifor Pharma, Eli Lilly, Pierre Fabre, McCann Health, Roularta, Teva, Gilead Sciences, Pfizer, Gilead, MSD; financial interests, institutional, invited speaker: Pfizer, Roche, Novartis, Eli Lilly, Mundi Pharma, MSD, Medscape, MSD; financial interests, institutional, other, consultancy: Roche; financial interests, personal, other, consultancy: Gilead, Novartis, MSD, Roche; financial interests, personal, invited speaker: AstraZeneca, Sanofi; financial interests, personal, advisory board: Seagen; financial interests, institutional, funding: Sanofi; non-financial interests, principal investigator: EORTC 1745-ETF-BCG trial; non-financial interests, other, committee member: ESMO Young Oncologists Committee; non-financial interests, invited speaker: BSMO; non-financial interests, other, committee member: ESMO Resilience Task Force; non-financial interests, advisory role: Commission personalized medecine Federal Government Belgium; non-financial interests, advisory role, external scientific advisor: European Medicine Agency. D.E.: financial interest, employed, stocks/shares in F.Hoffman-La Roche Ltd. A.G.: research funding to the Institut Paoli-Calmettes from MSD, Bristol Myers Squibb, Novartis, Boerhinger Roche, Sanofi, Daiichi Sankyo, and AstraZeneca; personal fees to the Institut Paoli-Calmettes from MSD, Seagen, and Novartis. F.G: financial interests, personal, advisory board: AstraZeneca, Pierre Fabre, Roche, Amgen, Servier, Sanofi, MSD, BMS. D.T.: financial interests, personal, advisory board: AstraZeneca, Daiichi Sankyo, Eli Lilly, Medscape, Roche, Novartis, Agendia, MSD; financial interests, personal, royalties: Pfizer, Roche, AstraZeneca; advisory board for Agendia, AstraZeneca, Daiichi Sankyo, Eli Lilly, Medscape, MSD, Novartis, Roche; travel fees from AstraZeneca, Pfizer, Roche. F.C.: financial interests, personal, advisory board: AstraZeneca, Eli Lilly, Roche, Merck, BMS, MSD; financial interests, institutional, research grant: AstraZeneca, Roche; financial interests, personal, royalties: AstraZeneca, Roche, Eli Lilly, Merck, BMS, MSD, Pfizer. T.v.d.M.: financial interests, personal, advisory board: Pfizer, Astellas, Bayer, MSD; financial interests, personal, royalties: Roche, Merck, Pfizer. J.-L.C.: financial interests, personal, advisory board: Lilly, Roche, Pfizer, BMS, Daiichi; financial interests, institutional, research grant: Roche, BMS, Amgen. J.M.F.: consulting or advisory roles for Roche, Pfizer, Novartis, and Eisai. H.B.: consulting or advisory role for AstraZeneca/Daiichi Sankyo; research funding from Bayer (Inst), travel, accommodations, expenses from Pfizer, AstraZeneca/Daiichi Sankyo. F.P.D.: financial interests, institutional, advisory board: Amgen, AstraZeneca, Daiichi Sankyo, Lilly, Gilead, Novartis, Pfizer, Pierre Fabre, Roche and Seagen, Amgen, AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Pfizer, Pierre Fabre, Roche and Seagen, Gilead; Financial Interests, Personal, Royalties: Amgen, Pfizer, Roche, Teva. F. Bazan: financial interests, personal, advisory board: Roche, Pfizer, Novartis, AstraZeneca, Clovis, SeaGen, Daiichi Sankyo. P.B.: Amgen, Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Ipsen, Janssen-Cilag, Merck KGaA, MSD, MSD Oncology, Pfizer (C/A), Astellas Pharma, Bristol-Myers Squibb, Ipsen, Janssen-Cilag, MSD, Pfizer (travel expenses and accommodations); N.I.: consulting for Ipsen and Transgene; receipt of travel support from PharmaMar and Pfizer; and advisory board participation for Daiichi Sankyo. E.A.: consultancy fee/honoraria from Eli Lilly, Sandoz, AstraZeneca. Research grant to my institution from Gilead; support to attend medical conferences (travel/accommodation/expenses) from Novartis, Roche, Eli Lilly, Genetic, Istituto Gentili, Daiichi Sankyo, AstraZeneca (all outside the submitted work). E.d.A.: financial interests, personal, advisory board: Roche/GNE, Novartis; financial interests, personal, invited speaker: Seattle Genetic, Zodiac, Libbs, Pierre Fabre; financial interests, institutional, research grant: Roche/GNE, AstraZeneca, GSK/Novartis, Servier; financial interests, institutional, other, travel grant: Roche/GNE. E.R.: funding to her institution from Bristol-Myers Squibb (BMS), AstraZeneca, Janssen-Cilag, Replimmune, and from Fonds Amgen France pour la Science et l’Humain and travel support from BMS, Hoffmann La Roche, AstraZeneca, Merck Sharp & Dohme. J.S.: permanent member of the Scientific Advisory Board and owns stocks of Surface Oncology, is member of the Scientific Advisory Board of Tarus Therapeutics, and is a member of the Scientific Advisory Board of Domain Therapeutics. C.S.: advisory board (receipt of honoraria or consultations fees): Astellas, Cepheid, Vertex, Seattle genetics, Puma, Amgen, Exact Sciences; participation in company sponsored speaker’s bureau: Eisai, Prime Oncology, Teva, Foundation Medicine, Exact Sciences; other support (travel, accommodation expenses): Roche, Genentech, Pfizer; M.I.: financial interests, personal, invited speaker: Novartis; financial interests, personal, advisory board: Novartis; financial interests, personal, other, independent monitoring committee: Seattle Genetics; financial interests, institutional, invited speaker: Pfizer, Roche, Natera; non-financial interests, invited speaker: EORTC; non-financial interests, officer: EORTC. M.P.: financial interests, personal, invited speaker: AstraZeneca, Lilly, MSD, Novartis, Pfizer; financial interests, personal, other, consultant: Camel-IDS/Precirix; financial interests, personal, advisory board: Immunomedics, Menarini, Odonate, Seattle Genetics, Immutep, SeaGen, Gilead, NBE Therapeutics, Frame Therapeutics; financial interests, personal, advisory board, consultant and invited speaker: Roche-Genentech; financial interests, personal, invited speaker, scientific board: Oncolytics; financial interests, institutional, research grant: AstraZeneca, Immunomedics, Lilly; financial interests, institutional, funding: Menarini, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier, Synthon. The other authors declare no competing interests.